XL413 activity depends on the cellular model. In 72-hour viability assays, the reported IC50 was 1.1 µM in Colo-205 cells and 22.9 µM in HCC1954 cells. Most lines in the eight-line 5 µM panel showed limited response. [1]
At 10 µM for 4 days, XL413 increased senescence-associated β-galactosidase staining in the displayed TP53-mutant liver-cancer models, whereas the displayed TP53-wild-type and non-transformed comparators showed little staining. These qualitative results describe the tested models. [2]
Inhibition of purified human CDC7–DBF4 kinase
Biochemical assay · Purified human CDC7 with DBF4 residues 341–674 [1]
XL413 inhibited DDK autophosphorylation with a reported IC50 of 22.7 nM. PHA-767491 was an active comparator (18.6 nM).
Literature-Reported Treatment Conditions
- Treatment concentration
- Increasing inhibitor concentrations; Figure 4 includes a no-inhibitor reference and no-DDK control.
- Exposure duration
- 5 min preincubation, followed by a 30 min kinase reaction at 30°C
- Method
- Radiometric DDK autophosphorylation assay; 20 ng DDK and 1.5 µM cold ATP plus radiolabelled ATP
- Reported limits
- Assay solvent is not specified in the adopted kinase-assay paragraph.
Methods and source locations
Compound reported in the paper: XL413 (BMS-863233); Compound label in the paper: XL413
Reported XL413 experiments; no salt conversion, tested-lot equivalence or Adooq lot validation is inferred.
Figure 4A-C; Results s3b; Methods s2a, s2c and s2e
DDK autophosphorylation inhibition: Radiolabelled bands quantified by ImageJ; GraphPad Prism fit. Figure 4 caption: mean of four independent measurements ± SD on separate days. — Figure 4C; Results s3b; Methods s2e
Cell-dependent XL413 viability response
Cell-based study · HCC1954 and Colo-205 human cancer cells; eight-line fixed-concentration panel [1]
At 5 µM for 72 h, XL413 had substantial activity in Colo-205 but limited effects in the other seven lines in Figure 3A. Dose-response IC50 values differed markedly between HCC1954 and Colo-205.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 µM in Figure 3A; increasing concentrations in Figure 3B,D
- Exposure duration
- 72 h after drug addition
- Method
- CellTiter-Glo ATP-based viable-cell readout relative to vehicle control
- Vehicle
- Vehicle control; DMSO is explicitly identified for the separate Figure 5 follow-up, but Figure 3 vehicle composition is not specified.
- Reported limits
- Exact dose-response series and vehicle percentage are not specified in the adopted caption/method paragraph. No values are estimated from curves.
Methods and source locations
Compound reported in the paper: XL413 (BMS-863233); Compound label in the paper: XL413
Reported XL413 experiments; no salt conversion, tested-lot equivalence or Adooq lot validation is inferred.
Figure 3A, B and D; Results s3a; Methods s2a and s2f
ATP-based viability inhibition in HCC1954: 72 h CellTiter-Glo; caption: mean of at least three separate measurements ± SD, reproducible on separate days. — Figure 3B; Results s3a
ATP-based viability inhibition in Colo-205: 72 h CellTiter-Glo; caption: mean of at least three separate measurements ± SD, reproducible on separate days. — Figure 3D; Results s3a
Model-dependent senescence-associated staining
Cell-based study · TP53-mutant liver-cancer cells Hep3B, Huh7, MHCC97H and PLC/PRF/5; TP53-wild-type SK-Hep1 and Huh6; non-transformed BJ, TIG-3, RPE-1 and MCF-10A cells [2]
After XL413 treatment, SA-β-Gal staining increased in the displayed TP53-mutant liver-cancer models, with little staining in the displayed wild-type and non-transformed comparators. This is a qualitative senescence-associated endpoint, not proof that every TP53-mutant cancer responds.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- 4 days
- Method
- SA-β-Gal staining with a commercial kit; representative microscopy
- Vehicle
- Figure 2b labels an untreated/control comparison; vehicle composition is not specified for this panel.
- Reported limits
- No numerical staining fraction is reported in the adopted panel/caption; none is inferred. Per-experiment supplier assignment and tested salt form are not given.
Methods and source locations
Compound reported in the paper: XL413 (BMS-863233); Compound label in the paper: XL413
Reported XL413 experiments; no salt conversion, tested-lot equivalence or Adooq lot validation is inferred.
Figure 2b and caption; Methods: Compounds and antibodies; SA-β-Gal staining
Senescence-associated β-galactosidase staining: Figure 2b is representative of three independent biological experiments; no quantitative percentage extracted. — Figure 2b and caption